NFL BIOSCIENCES (EPA:ALNFL) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
NFL BIOSCIENCES

BRIEF

published on 07/03/2025 at 08:35, 5 months 1 day ago

NFL Biosciences Expands Clinical Leadership Amid NFL-101 Development

Clinical Development Smoking Cessation NFL-101 Biopharmaceuticals Dr. Yannick Plétan
REGULATED PRESS RELEASE

published on 07/03/2025 at 08:30, 5 months 1 day ago

NFL Biosciences strengthens its clinical leadership by expanding Dr. Yannick Plétan’s role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoking cessation
NFL Biosciences strengthens clinical leadership by expanding Dr. Yannick Plétan’s role as CMO to accelerate clinical development of NFL-101 in smoking cessation

NFL Biosciences Clinical Development Smoking Cessation NFL-101 Dr. Yannick Plétan
BRIEF

published on 07/02/2025 at 18:05, 5 months 2 days ago

Half-yearly report on the NFL BIOSCIENCES liquidity contract

NFL Biosciences Liquidity Contract INVEST SECURITIES Biopharmaceuticals Stock Market Transactions
BRIEF

published on 05/23/2025 at 07:35, 6 months 12 days ago

NFL Biosciences Successfully Raises €3 Million in Capital Increase

Capital Increase Investor Participation Oversubscription NFL-101 Trial Phase 3 Funding
REGULATED PRESS RELEASE

published on 05/23/2025 at 07:30, 6 months 12 days ago

NFL Biosciences announces the success of its capital increase capped at €3 million
NFL Biosciences successfully completes €3 million capital increase with oversubscription, involving international and French investors; plans Phase 3 clinical trial for smoking cessation drug NFL-101

NFL Biosciences Investors Capital Increase Smoking Cessation Phase 3 Clinical Trial
BRIEF

published on 05/22/2025 at 17:50, 6 months 13 days ago

NFL Biosciences Announces €2.2 Million Capital Increase

NFL Biosciences Clinical Trials Capital Increase Biopharmaceuticals Investment Risks
REGULATED PRESS RELEASE

published on 05/22/2025 at 17:45, 6 months 13 days ago

NFL Biosciences launches a capital increase of approximately €2.2 million
NFL Biosciences launches a €2.2 million capital increase through global offering for smoking cessation drug development. Subscription price: €1.20/share

NFL Biosciences Capital Increase Smoking Cessation Subscription Price Global Offering
BRIEF

published on 05/21/2025 at 17:50, 6 months 14 days ago

NFL Biosciences General Meeting Results

NFL Biosciences Shareholders Biopharmaceuticals Resolutions General Assembly
BRIEF

published on 05/12/2025 at 08:35, 6 months 23 days ago

NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement

NFL Biosciences NFL-101 Phase 3 Trials Tobacco Addiction Scientific Committee
REGULATED PRESS RELEASE

published on 05/12/2025 at 08:30, 6 months 23 days ago

NFL Biosciences strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its first-in-class therapy for tobacco addiction
NFL Biosciences strengthens scientific committee with world-class experts for Phase 3 development of NFL-101, a breakthrough therapy for tobacco addiction

NFL Biosciences NFL-101 Phase 3 Development Tobacco Addiction Scientific Committee

1 2 ... 5

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 41 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 46 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 16 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 11 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 16 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 46 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 25 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 51 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 1 minute ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 6 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 16 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 31 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 32 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 15 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE